Entest BioMedical Signs LOI with Quantum Advisors to Coordinate Development of COPD Stem Cell Therapy

$832 Billion in COPD Medical Related Costs Projected over Next 20 Years in United States Means Potentially Huge Market for Entest’s Stem Cell Therapy

• Press Release
• Source: Entest BioMedical Inc.
• On 8:00 am EST, Tuesday November 3, 2009

SAN DIEGO--(BUSINESS WIRE)--Entest BioMedical Inc. (OTCBB: ENTB - News) announced today that it has signed a Letter of Intent with Quantum Advisors, a San Diego based biotechnology consulting firm, to assist Entest with the development of its Stem Cell Therapeutic Treatment for Chronic Obstructive Pulmonary Disease (COPD).

Related Quotes

Symbol	Price	Change
BMSN.OB	0.08	0.00

{"s" : "bmsn.ob,entb.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

An Entest spokesperson stated that Quantum’s anticipated role in this research will be to work with Company scientists, Contract Research Organizations (CROs) and Regulatory authorities in moving forward with clinical testing of Entest’s patent pending technology. Quantum will also be involved with assisting the Company with its Investigational New Drug (IND) submission to the FDA.

David Koos, Entest’s Chairman & CEO, said, “Our relationship with Quantum is extremely valuable to our Company. Not only is it planned for them to be working with us to develop our stem cell therapy for COPD, it is also planned that they will help identify appropriate Joint Venture candidates for commercialization of this technology. What this means to COPD patients -- we are going to do all that is possible to bring this treatment for COPD to doctors and hospitals at the earliest possible date.”

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB - News) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN - News). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Entest BioMedical Inc.
David R. Koos, Chairman & CEO
619-702-1404 Direct
619-330-2328 Fax
info@EntestBio.com
www.EntestBio.com